id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-0617-0007,FDA,FDA-2016-E-0617,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2017-09-20T04:00:00Z,2017,9,2017-09-20T04:00:00Z,,2017-09-20T13:39:18Z,,0,0,0900006482b61cc0
FDA-2016-E-0617-0006,FDA,FDA-2016-E-0617,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-12-08T05:00:00Z,2016,12,2016-12-08T05:00:00Z,,2016-12-08T18:28:22Z,,0,0,09000064823ee33b
FDA-2016-E-0617-0005,FDA,FDA-2016-E-0617,Determinations of Regulatory Review Periods for Purposes of Patent Extension: BEXSERO,Notice,Determinations,2016-12-05T05:00:00Z,2016,12,2016-12-05T05:00:00Z,2017-06-06T03:59:59Z,2016-12-05T16:32:55Z,2016-29025,0,0,09000064823e018b
FDA-2016-E-0617-0004,FDA,FDA-2016-E-0617,Letter from the U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2016-10-13T04:00:00Z,2016,10,2016-10-13T04:00:00Z,,2016-10-13T14:37:10Z,,0,0,09000064822e9e4d
FDA-2016-E-0617-0003,FDA,FDA-2016-E-0617,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2016-04-25T04:00:00Z,2016,4,2016-04-25T04:00:00Z,,2016-04-25T21:16:05Z,,0,0,0900006481f78994
FDA-2016-E-0617-0002,FDA,FDA-2016-E-0617,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2016-02-24T05:00:00Z,2016,2,2016-02-24T05:00:00Z,,2016-02-24T19:02:49Z,,0,0,0900006481e76a04
FDA-2016-E-0617-0001,FDA,FDA-2016-E-0617,Patent Extension Application from Morrison & Foerster LLP (on behalf of GlaxoSmithKline Biologicals SA),Other,Application,2016-02-24T05:00:00Z,2016,2,2016-02-24T05:00:00Z,,2016-02-24T19:02:42Z,,0,0,0900006481e763c5